
Find a trial

PACT partnership with HealthMatch to help patients access clinical trials
Finding and accessing clinical trials can be difficult for Pulmonary Fibrosis patients. PACT has partnered with HealthMatch to make this process easier and more efficient. Use the link below to find out more about matching for current and future Pulmonary Fibrosis clinical trials and create a profile.
Visit HealthMatchDeciding to be part of a clinical trial is a very personal decision. People eligible to participate in a clinical trial are limited to a group with very specific characteristics. Please see below clinical trials that are currently recruiting in Australasia.
Recruiting Trials
Trial | Title | Status | More Information |
---|---|---|---|
STARSCAPE WA42293 | A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis. | Recruiting | Clinicaltrials.gov ID: NCT04552899 |
GALACTIC-1 | A randomised, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in participants with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler (DPI) over 52 weeks. | Recruiting | Clinicaltrials.gov ID: NCT03832946 |
TELO-SCOPE | Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis. | Recruiting | Clinicaltrials.gov ID: NCT04638517 |
PFOX | PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial | Recruiting | Clinicaltrials.gov ID: NCT03737409 |
HIIT | High intensity interval training in fibrotic interstitial lung disease | Recruiting | Clinicaltrials.gov ID: NCT03800914 |
GRIPF | Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF) | Recruiting | Not Applicable |
Trials Closed to Recruitment
Trial | Title | Status | More Information |
---|---|---|---|
BI 1305-0013 | Title: A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally. | Closed to Recruitment | Clinicaltrials.gov ID: NCT04419506 |
ATLAS AP01-002 | A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis | Closed to Recruitment | Clinicaltrials.gov ID: ACTRN12618001838202 |
Trail1 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD) | Closed to recruitment The TRAIL1 study continued enrolment through the planned timeline, but was somewhat impacted by COVID and did not meet enrolment goals. | Clinicaltrials.gov ID: NCT02808871 |
AGN120-1 | An Open Label Study of the Efficacy, Safety and Tolerablity of Np-120 on Idiopathic Pulmonary Fibrosis and its Associated Cough | Closed to Recruitment | Clinicaltrials.gov ID: NCT04318704 |
Zephyrus FGCL-3019-091 | FGCL-3019-091 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | Closed to recruitment | Clinicaltrials.gov ID: NCT03955146 |
BMS IM027-040 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis. | Closed to recruitment |
Completed Trials
Trial | Title | Status | More Information |
---|---|---|---|
HHF-ILD | Handheld fan for breathlessness in interstitial lung disease | Study completed | Clinicaltrials.gov ID: ACTRN12618001949279 |
COLDICE | Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE | Study completed | Clinicaltrials.gov ID: ACTRN12615000718549 |
Discontinued Trials
Trial | Title | Status | More Information |
---|---|---|---|
SCENIC | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial | Discontinued The SCENIC study was terminated due to the impact of COVID-19. The study was being conducted across 11 countries and while the impact was minimal in Australasia this was not the case in the other regions. |
Clinicaltrials.gov ID: NCT03864328 |
Isabela 1&2 | A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis | Discontinued The decision to discontinue the ISABELA Phase 3 clinical studies was based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies. |
Clinicaltrials.gov ID: NCT0371l-162 Clinicaltrials.gov ID: NCT03733444 |
Blade Therapeutics | A Phase 1a/1b, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Subjects with Lung Fibrosis or Liver Fibrosis | Discontinued | Clinicaltrials.gov ID: NCT03559166 |
SPIRIT | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Discontinued | ClinicalTrials.gov ID: NCT03573505 |
PACT is funded by the NHMRC Centre of Research Excellence in Pulmonary Fibrosis and generously supported by:




